In addition, mice whose cancers have been eradicated with IL-12 do not develop the same cancers again if they are artificially reintroduced in the animals, suggesting that their bodies have developed an immune memory of the cancers. IL-12's apparent low toxicity and ability to remain active in the body for an extended time make it an excellent choice for human clinical trials. In one, the IL-12 protein was injected into patients with advanced disease. This preliminary study accrued patients with different cancers, excluding leukemia and lymphoma. Another clinical study that began August 1995 involves IL-12 gene transfer to patients with advanced cancer, allowing continuous production of this cytokine inside the body.
Clinical trials are in the earliest phases of development.
Although substantial interest exists for studies of IL-12, it will likely take several years before this therapy could become standard. For more information visit the University of Pittsburgh Cancer Institute Web site. UPMC Health System News Bureau pages have been accessed times since June 1, 2000.